COVIDIEN LLC MAHURKAR and Argyle acute hemodialysis catheters, Material numbers 8813793009 8813793013 8813794005 8813794009 8813816005 8813816009 8813817005 8813817009 8815668007 8815668011 8815668021 8815668027 8817142005 8817143005 8817145005 8817146001 8817146007 8817149007 8817232018 8817232019 8817277007 8817277011 8817277021 8817277027 8830414001 8830414002 8830415001 8830415003 8830416001 8830416003 8830416021 8830416023 8831173010 8831173011 8831173012 8831661001 8 Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
MAHURKAR and Argyle acute hemodialysis catheters, Material numbers 8813793009 8813793013 8813794005 8813794009 8813816005 8813816009 8813817005 8813817009 8815668007 8815668011 8815668021 8815668027 8817142005 8817143005 8817145005 8817146001 8817146007 8817149007 8817232018 8817232019 8817277007 8817277011 8817277021 8817277027 8830414001 8830414002 8830415001 8830415003 8830416001 8830416003 8830416021 8830416023 8831173010 8831173011 8831173012 8831661001 8
Brand
COVIDIEN LLC
Lot Codes / Batch Numbers
All lots
Products Sold
All lots
COVIDIEN LLC is recalling MAHURKAR and Argyle acute hemodialysis catheters, Material numbers 8813793009 8813793013 881379400 due to The priming volume values printed on the MAHURKA and Argyle acute catheters and Instructions for Use (IFU) are higher than the volumes required to fil. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
The priming volume values printed on the MAHURKA and Argyle acute catheters and Instructions for Use (IFU) are higher than the volumes required to fill each lumen.
Recommended Action
Per FDA guidance
On April 29, 2019, consignees were notified by letter via Federal Express and/or federal mail. The Field Safety Alert informed customers that the priming volume values printed on the MAHURKAR and Argyle acute catheters and Instructions for Use are higher than the volumes required to fill each lumen. The firm will update the IFU for the affected products to provide clarity on the printed priming volumes. In the meantime, the firm recommends the use of a non-heparinized lock solution, such as 4% sodium citrate or 1000 U/mL heparin to mitigate potential risk associated with unintended administration of additional concentrated heparin. The firm asks that customers complete and return the acknowledgement form accompanying the notification even if they do not have affected inventory. If you have experienced quality problems or adverse events, you may contact the firm at quality.assurance@covidien.com.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026